Amanda Wilson
A5054532783- Vaccine Coverage and Hesitancy
- SARS-CoV-2 and COVID-19 Research
- COVID-19 epidemiological studies
- COVID-19 Clinical Research Studies
- Climate change impacts on agriculture
- Data-Driven Disease Surveillance
- Viral gastroenteritis research and epidemiology
- Influenza Virus Research Studies
Moderna Therapeutics (United States)
2024
University of Virginia
2023
Urology of Virginia
2023
Johns Hopkins University
2022
University Vascular Associates
2022
Johns Hopkins University Applied Physics Laboratory
2022
The COVID-19 Scenario Modeling Hub convened nine modeling teams to project the impact of expanding SARS-CoV-2 vaccination children aged 5-11 years on burden and resilience against variant strains.Teams contributed state- national-level weekly projections cases, hospitalizations, deaths in United States from September 12, 2021 March 2022. Four scenarios covered all combinations 1) (or not) (starting November 1, 2021), 2) emergence a more transmissible than Delta (emerging 15, 2021)....
SARS-CoV-2 vaccination of persons aged 12 years and older has reduced disease burden in the United States. The COVID-19 Scenario Modeling Hub convened multiple modeling teams September 2021 to project impact expanding vaccine administration children 5-11 old on anticipated resilience against variant strains.
Background: This study evaluated the effectiveness of Moderna's updated mRNA–1273 vaccine targeting KP.2 variant, compared to people who did not receive any 2024–2025 COVID–19 vaccine, in preventing COVID–19–associated hospitalizations and medically attended among adults aged ≥ 18 years United States during season. Methods: Data were extracted from linked administrative healthcare claims electronic health records (EHR) for vaccinations 23 August 2024 through 24 December followed 31 2024. We...
In September 2023 the Food and Drug Administration (FDA) approved an updated mRNA COVID-19 vaccine targeting XBB.1.5 sublineage. This study evaluates effectiveness of mRNA-1273.815, a 2023–2024 Omicron XBB.1.5-containing in preventing COVID-19-related hospitalizations medically attended US adults aged ≥ 18 years. observational, matched cohort used medical pharmacy claims data from HealthVerity. Adults vaccinated with mRNA-1273.815 between 12, 2023, December 31, were followed through January...
Abstract Our ability to forecast epidemics more than a few weeks into the future is constrained by complexity of disease systems, our limited measure current state an epidemic, and uncertainties in how human action will affect transmission. Realistic longer-term projections (spanning weeks) may, however, be possible under defined scenarios that specify critical epidemic drivers, with additional benefit such can used anticipate comparative effect control measures. Since December 2020, U.S....
Abstract Importance COVID-19 continues to cause significant hospitalizations and deaths in the United States. Its continued burden impact of annually reformulated vaccines remain unclear. Objective To project from April 2023–April 2025 under two plausible assumptions about immune escape (20% per year 50% year) three possible CDC recommendations for use (no vaccine recommendation, vaccination those aged 65+, all eligible groups). Design The Scenario Modeling Hub solicited projections...